Considering the potential detrimental role of TLR4-TRAM-TRIF signaling in sepsis (12, 20, 21) and excessive TLR4 signaling in other inflammatory diseases (reviewed in references 1, 22, 23, 24, 25, 26), this peptide could be a new therapeutic agent with favorable properties compared with previously developed TIR-domain–derived peptides or TIR domain-targeting small molecules (14, 15, 16, 17, 27). This evidence concerns the gene TLR4 and Sepsis.